Molecule

Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results

Retrieved on: 
木曜日, 5月 9, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Molecule, PALISADE, EAP, American College, FCS, Risk, PIN, Hypertriglyceridemia, Arrowhead, APOC3, RNA, Webcast, Triglyceride, Cardiology, Patient, Cardiovascular disease, Diagnosis, Clinical trial, JAMA Cardiology, Amgen, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024.
  • The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m.
  • Received a $50 million milestone payment from Royalty Pharma plc, which was paid in the third quarter of fiscal 2024, following the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen.
  • Each event will feature presentations by Arrowhead team members and external key opinion leaders, who will discuss the respective disease areas and treatment landscapes.

Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Retrieved on: 
木曜日, 5月 9, 2024
Molecule, Idiopathic pulmonary fibrosis, Investment, Safety, Research, GIPR, IPF, GPCR, Growth, Obesity, Therapy, G&A, SAN, Pharmaceutical industry

SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate achievements.

Key Points: 
  • High level PK study results are expected in June 2024.
  • The Company plans to initiate a global Phase 2b obesity study of GSBR-1290 in the fourth quarter of 2024.
  • The Company plans to initiate a Phase 2 study in T2DM in the second half of 2024.
  • R&D Expenses: Research and development (R&D) expenses for the first quarter of 2024 were $20.7 million, as compared to $13.1 million for the same period in 2023.

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

Retrieved on: 
水曜日, 5月 8, 2024
ENDO, Molecule, Science, Efficacy, Hyperplasia, ACTH, Safety, CAH, ASD, Policy, Abstract, Serum, Innovation, Lanreotide, Octreotide, Barrow Neurological Institute, Endocrine Society, Single Center, Congenital adrenal hyperplasia, A4, Endocrine system, Pharmaceutical industry

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced five abstracts from its clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston, Massachusetts.

Key Points: 
  • One presentation will showcase initial safety and key biomarker efficacy findings in CAH, including rapid and profound reductions in androstenedione (A4) and 17-hydroxyprogesterone levels in participants, from the Phase 2 open label TouCAHn study.
  • A second presentation includes data from a Phase 1b/2a open-label single center study of atumelnant in ACTH-dependent Cushing’s syndrome and will feature the first evidence of rapid and sustained cortisol reductions in participants.
  • Crinetics will also have a poster presentation with data from the Phase 3 PATHFNDR-2 study evaluating paltusotine in acromegaly patients who were medically untreated.
  • Data from the PATHFNDR program will be featured in a Science and Innovation Theater led by Dr. Kevin C.J.

Neurenati Therapeutics Strengthens Its Board of Directors With the Appointment of Dr. Marielle Cohard-Radice

Retrieved on: 
水曜日, 5月 8, 2024
Health, Genetics, Other Health, Research, Science, Pharmaceutical, Biotechnology, B cell, Enteric nervous system, DevOps, IRIC, Therapy, Molecule, Daiichi Sankyo, Hirschsprung's disease, Management

Neurenati Therapeutics, a pediatric rare diseases-focused company, is delighted to announce the appointment of a highly-experienced executive in the pharma industry as an independent board member.

Key Points: 
  • Neurenati Therapeutics, a pediatric rare diseases-focused company, is delighted to announce the appointment of a highly-experienced executive in the pharma industry as an independent board member.
  • Dr Marielle Cohard-Radice is a gastroenterologist who held various executive positions in several therapeutic areas over three decades.
  • Welcome on the board of directors,” added Maxime Ranger, CEO of Neurenati.
  • Looking forward to supporting Neurenati in its efforts,” said Dr. Cohard-Radice
    Both independent board members, Dr Alexandre Lebeaut and Dr Marielle Cohard-Radice will assist Neurenati to create its scientific and clinical advisory board in upcoming months.

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Retrieved on: 
月曜日, 5月 6, 2024
Research, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Education, FDA, CFO, Disorder, Regenerative medicine, University of California, Alexion Pharmaceuticals, PDUFA, Arena Pharmaceuticals, Danon disease, European Medicines Agency, Strategic planning, UCLA, Food, Molecule, Stanford University, Empire, BLA, Medication, Corporate communication, Definitive, Fanconi anemia, Patient, Increment, Safety, Rare disease, Regeneron Pharmaceuticals, AAV, Immunology, EMA, FA, Division, PKD, University, Marketing, MAA, Cell, Biologics license application, Pharmacology, Rare Disease Day, Disease, Mirati Therapeutics, Haematopoietic system, Gene, Society, Pyruvate kinase deficiency, Liberty Science Center, Annual general meeting, Pharmaceutical industry

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.
  • In April, Rocket announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for RP-L102 for the treatment of FA.
  • MAA acceptance was based on positive, previously disclosed data from the global RP-L102 Phase 1/2 clinical trial.
  • Mr. Ondrey was previously the CFO at Mirati Therapeutics and has held multiple senior finance leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals.

Think Bioscience extends Seed Round to accelerate pocket-finding platform

Retrieved on: 
火曜日, 5月 7, 2024
Molecule, Protein, SAB, GV (company), Computational chemistry, Genentech, Research, Gold, Therapy, Senior, GTPase, Drug development, Growth, Protein tyrosine phosphatase, Pharmaceutical industry

BOULDER, Colo., May 7, 2024 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has announced a $6M Seed Expansion. Existing investors are joined by YK Bioventures, bringing total funding to $26M. The additional raise will accelerate the company's pipeline and expand their unique approach for finding new functional pockets on challenging targets.

Key Points: 
  • BOULDER, Colo., May 7, 2024 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has announced a $6M Seed Expansion.
  • The additional raise will accelerate the company's pipeline and expand their unique approach for finding new functional pockets on challenging targets.
  • Gary Yeung, a managing partner at YK Bioventures, added, "We invested in Think Bioscience because of its transformational platform for new discoveries.
  • "We look forward to working even more closely with Wendy," said Dr. Jerome Fox, co-founder and CEO at Think Bioscience.

Global RNAi Therapeutics Market Insights & Forecasts with Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com

Retrieved on: 
金曜日, 5月 3, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Molecule, MicroRNA, Investment, RNA interference, Hospital, Infection, RNA, Research, Liver, HTS, Therapy, DSM-IV codes, COVID-19, Prevalence, Row

The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • The global RNAi therapeutics market is expected to record a value of US$1.39 billion in 2028, progressing at a CAGR of 9.98%, over the period 2024-2028.
  • Whereas, the global RNAi therapeutics market is split into research & academic laboratories and hospitals & diagnostic laboratories, in terms of end-user.
  • The report provides a comprehensive analysis of the global RNAi therapeutics market segmented on the basis of molecule type, application, end-user and region, with potential impact of COVID-19.

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

Retrieved on: 
木曜日, 5月 2, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Molecule, Small RNA, AMGN, RNA interference, Risk, Partnering, Arrowhead, APOC3, Moyamoya disease, RNA, Apolipoprotein C-III, Trial, Patient, Myocardial infarction, Cardiovascular disease, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX).
  • This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN).
  • Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from Amgen and $110 million from Royalty Pharma in aggregate development, regulatory, and sales milestone payments associated with olpasiran.
  • “Our pipeline of wholly owned or partnered TRiMTM-enabled candidates now includes three programs in Phase 3 - olpasiran, fazirsiran, and plozasiran.

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024

Retrieved on: 
水曜日, 4月 24, 2024
Molecule, Stroke, Safety, Pharmacokinetics, CHDR, Psychedelic drug, Brain, AGN, DMT, Conference, Research, Patient, Plasma, Pharmaceutical industry

AGN Neuro is the world’s first company to investigate DMT for the treatment of stroke and its ability to promote neuroplasticity in the healing of brain injuries.

Key Points: 
  • AGN Neuro is the world’s first company to investigate DMT for the treatment of stroke and its ability to promote neuroplasticity in the healing of brain injuries.
  • In addition, several pharmacodynamic measures believed to be associated with neuroplasticity, including both measurements of biochemical markers and electroencephalographic readings, were recorded.
  • AGN Neuro is the first company to test DMT at single escalating concentrations with an IV dose for a 6-hour duration.
  • Based on the positive data from the Phase 1 DMT stroke clinical trial, the Company plans to begin a Phase 2a clinical trial in acute ischemic stroke patients in 2024.

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Retrieved on: 
水曜日, 4月 17, 2024
Molecule, Neuroimaging, American Academy, Brain, Iron, Oxidative stress, MSA, AFL, Poster, Disease, Vanderbilt University, Substantia nigra, Plasma, ASX, Pathology, Neurofilament, Forecasting, Macaque, Nerve, Multiple system atrophy, Patient, Treatment, Observational study, AAN, CSF, Neuron, Biomarker, Annual general meeting, Vanderbilt University Medical Center, Therapy, Cerebrospinal fluid, Parkinsonism, ATH, Frasier, SAN, Medical imaging

MELBOURNE, Australia and SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters were presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA. Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.

Key Points: 
  • Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.
  • At AAN we reported the baseline characteristics from our ATH434-201 Phase 2 trial including fluid biomarkers and neuroimaging data.
  • The data showed increased iron in areas of pathology and elevated plasma Neurofilament Light Chain (NfL) levels at baseline that correlated significantly with disease severity.
  • Plasma NfL significantly increased over 12 months, and both plasma and CSF NfL were associated with disease progression in MSA.